✦ LIBER ✦

Commentary on ‘Nutritional support in children and young people with cancer undergoing chemotherapy’

✍ Scribed by E. J. Ladas; Paul Rogers

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 51 KB
Volume: 6
Category: Article
ISSN: 1557-6272
DOI: 10.1002/ebch.802

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Summary of ‘Nutritional support in child

Summary of ‘Nutritional support in children and young people with cancer undergoing chemotherapy’

✍ Evidence-Based Child Health Editorial Office 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

Parenteral nutritional support in childr

Parenteral nutritional support in children with cancer

✍ Robert M. Filler; Norman Jaffe; J. Robert Cassady; Demetrius G. Traggis; John B. 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 366 KB 👁 3 views

Changes in markers of ovarian reserve an

Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy

✍ Bo Yu; Nataki Douglas; Michel J. Ferin; Gary S. Nakhuda; Katherine Crew; Rogerio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

Commentary on assessing health-related q

Commentary on assessing health-related quality of life in children with cancer

✍ Grace Ann Monaco 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 31 KB 👁 3 views

Commentary on the SIOP report?valid info

Commentary on the SIOP report?valid informed consent and participative decision making in children with cancer and their parents

✍ Farnell, Sheila M. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB

P53 is the strongest predictor of surviv

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support

✍ Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Sol 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 3 views

## Abstract Our purpose was to determine the predictive value of tumor biologic parameters in patients with HRPBC who received HDCT with ASCT as first‐line treatment. From September 1992 to May 2000, 149 stage II or III HRPBC patients were enrolled in a single‐arm trial using a tandem HDCT regimen